220
TL1A DRIVES ILC-MEDIATED GRANULOPOIESIS AND COLITIS ASSOCIATED CANCER
Date
May 18, 2024
Tracks
Related Products
Deciphering the Innate Immune Landscape and Host-Microbial Interactions in IBD
MACROPHAGE LRRK2 HYPERACTIVITY IMPAIRS AUTOPHAGY AND INDUCES PANETH CELL DYSFUNCTION AND INTESTINAL INFLAMMATION
SAFETY OF IMMUNOSUPPRESSION IN A PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF CANCER: THE SAPPHIRE REGISTRY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A CLINICAL SCORE FOR UC2CD, A NOVEL SUBGROUP IN INFLAMMATORY BOWEL DISEASES (IBD) WITH DISTINCT SEROLOGICAL, GENETIC AND CLINICAL FEATURES
BACKGROUND: Previously we identified that patients with initial diagnosis of Ulcerative Colitis (UC) but subsequently had a diagnosis change to Crohn’s Disease (CD) (UC2CD) are a unique IBD subgroup with distinct serological, genetic and clinical features, including non-response to anti-TNF treatme…